Effect of Dezocine Combined With Sufentanil on the Quality of Postoperative Recovery and Analgesic Effect in Patients Undergoing Thoracic Surgery

Exclusion Criteria

• •1. Inability to understand the nature, significance, possible benefits, possible inconveniences and potential risks of the trial, or inability to understand the study procedures and pain-related assessment methods;
• •2. Patients who cannot accept the postoperative analgesia specified in the protocol;
• •3. Clinician judgment: liver and kidney dysfunction has clinical significance (ALT and AST \> 2 times the upper limit of normal; BUN and/or Urea \> 2 times the upper limit of normal, Cr \> 2 times the upper limit of normal; dialysis treatment within 28 days before surgery), or coagulation dysfunction has clinical significance (PT or APTT or TT \> the upper limit of normal), or poor blood pressure control (sitting SBP \> 160 mmHg or SBP \< 90 mmHg), or oxygen saturation (without oxygen) \< 94%;
• •4. Patients with high risk of respiratory depression or respiratory depression (such as sleep apnea syndrome);
• •5. Patients who are allergic to the test drugs (dezocine, sufentanil);
• •6. History of bronchial asthma;
• •7. Patients with hypothyroidism;
• •8. Patients with uncontrolled gastrointestinal ulcers, gastrointestinal bleeding or perforation before surgery; or patients with paralytic ileus;
• •9. Patients with chronic (continuous 3 months or intermittent up to 6 months) pain associated with non-surgical sites;
• •10. Craniocerebral injury, possible intracranial hypertension, cerebral aneurysm, cerebrovascular accident history or suffering from central nervous system diseases (such as epilepsy);
• •11. Suffering from mental system diseases (such as depression), or long-term use of psychotropic drugs;
• •12. Patients who cannot evaluate the pain intensity after surgery or are transferred to ICU;
• •13. Evidence of severe cardiac dysfunction (NYHA class III and IV), unstable angina pectoris or acute myocardial infarction within 6 months before enrollment;
• •14. Estimated operative blood loss greater than 1000 ml or other serious complications during surgery;
• •15. Patients with a history of drug abuse, drug abuse and alcohol abuse within 2 years before the start of the screening period; Alcohol abuse was defined as regular consumption of more than 14 drinks/week (1 drink = 150 mL wine or 360 mL beer or 45 mL spirits);
• •16. Patients who have been taking opioids for a long time (continuous use for 1 month or intermittent use for up to 3 months), or who are tolerant to opioids;
• •17. Patients who have used monoamine oxidase inhibitors within 2 weeks;
• •18. Participating in any clinical trial as a subject within 3 months;
• •19. Pregnant or lactating women or patients with fertility plan within 6 months (including men);
• •20. Patients who are judged unsuitable for participation by other investigators.